MedTrace Logo

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

NCT02500511 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2016-04-12

No results posted yet for this study

Summary

To determine the persistence of protective antibody levels for subjects who seroconverted after vaccination with NmVac4-A/C/Y/W-135-DT™

Participants in trial # JN-NM-002, who seroconverted for serogroups A and C will be contacted and asked to provide a blood sample at 12-24 months after vaccination with NmVac4-A/C/Y/W-135-DT.

Serum Bactericidal Assays will be performed to evaluated duration of protective antibody titer for NmVac4-A/C/Y/W-135-DT for all four serogroups. To determine if subjects who seroconverted with lower titers retain protective levels of antibody (titer ≥:8) at 12-24 months after vaccination.

Conditions

  • Meningococcal Meningitis
  • Meningococcal Infections

Interventions

BIOLOGICAL

NmVac4-A/C/Y/W-135-DT™

no intervention in this study, received test vaccine in trial JN-NM-002

Sponsors & Collaborators

  • JN-International Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Alberto Yataco, MD · IRC Clinics

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-08-31
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02500511 on ClinicalTrials.gov